These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30592139)
1. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo. Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139 [TBL] [Abstract][Full Text] [Related]
2. PDGFRβ-targeted TRAIL specifically induces apoptosis of activated hepatic stellate cells and ameliorates liver fibrosis. Li R; Li Z; Feng Y; Yang H; Shi Q; Tao Z; Cheng J; Lu X Apoptosis; 2020 Feb; 25(1-2):105-119. PubMed ID: 31894448 [TBL] [Abstract][Full Text] [Related]
3. The improving effects on hepatic fibrosis of interferon-γ liposomes targeted to hepatic stellate cells. Li Q; Yan Z; Li F; Lu W; Wang J; Guo C Nanotechnology; 2012 Jul; 23(26):265101. PubMed ID: 22700686 [TBL] [Abstract][Full Text] [Related]
4. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Oh Y; Park O; Swierczewska M; Hamilton JP; Park JS; Kim TH; Lim SM; Eom H; Jo DG; Lee CE; Kechrid R; Mastorakos P; Zhang C; Hahn SK; Jeon OC; Byun Y; Kim K; Hanes J; Lee KC; Pomper MG; Gao B; Lee S Hepatology; 2016 Jul; 64(1):209-23. PubMed ID: 26710118 [TBL] [Abstract][Full Text] [Related]
5. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. Li F; Li QH; Wang JY; Zhan CY; Xie C; Lu WY J Control Release; 2012 Apr; 159(2):261-70. PubMed ID: 22226772 [TBL] [Abstract][Full Text] [Related]
6. Long-Circulating Liposomal Delivery System Targeting at PDGFR-β Enhances the Therapeutic Effect of IFN-α on Hepatic Fibrosis. Li Q; Yu Q; Ju J; You T; Yan Z; Nan X; Zhong J; Zhou JE Curr Pharm Des; 2017; 23(20):3034-3046. PubMed ID: 27928957 [TBL] [Abstract][Full Text] [Related]
7. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis. Li R; Zhang J; Liu Q; Tang Q; Jia Q; Xiong Y; He J; Li Y Acta Biomater; 2023 Sep; 168():484-496. PubMed ID: 37392933 [TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells. Xia S; Liu Z; Cai J; Ren H; Li Q; Zhang H; Yue J; Zhou Q; Zhou T; Wang L; Liu X; Zhou X J Control Release; 2023 Mar; 355():54-67. PubMed ID: 36693527 [TBL] [Abstract][Full Text] [Related]
9. Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway. Sun Z; Guo Y; Xu X; Zhou C; Luo X; Shen Z; Shen B; Wang J; Lu J; Zhang Q; Shen F; Yu L; Ye Y; Zhang L; Luo Y; Qu Y; Cai X; Dong H; Lu L J Gastroenterol Hepatol; 2024 Aug; 39(8):1695-1703. PubMed ID: 38804845 [TBL] [Abstract][Full Text] [Related]
10. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of human hepatic stellate cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by leflunomide. Tang X; Yang J; Li J Biol Pharm Bull; 2009 Jun; 32(6):963-7. PubMed ID: 19483299 [TBL] [Abstract][Full Text] [Related]
12. Smad2 increases the apoptosis of activated human hepatic stellate cells induced by TRAIL. Xu F; Zhou D; Meng X; Wang X; Liu C; Huang C; Li J; Zhang L Int Immunopharmacol; 2016 Mar; 32():76-86. PubMed ID: 26802603 [TBL] [Abstract][Full Text] [Related]
13. Taurine attenuates activation of hepatic stellate cells by inhibiting autophagy and inducing ferroptosis. Li S; Ren QJ; Xie CH; Cui Y; Xu LT; Wang YD; Li S; Liang XQ; Wen B; Liang MK; Zhao XF World J Gastroenterol; 2024 Apr; 30(15):2143-2154. PubMed ID: 38681990 [TBL] [Abstract][Full Text] [Related]
14. Targeting delivery of a novel TGF-β type I receptor-mimicking peptide to activated hepatic stellate cells for liver fibrosis therapy via inhibiting the TGF-β1/Smad and p38 MAPK signaling pathways. Liu X; Wang X; Xu L; Fan J; Yuan Q; Zhang F; Liu J; Qiu X; Li Y; Xia C; Liu H Eur J Pharmacol; 2024 Aug; 977():176708. PubMed ID: 38843945 [TBL] [Abstract][Full Text] [Related]
15. Reactive Oxygen Species-Responsive Polypeptide Drug Delivery System Targeted Activated Hepatic Stellate Cells to Ameliorate Liver Fibrosis. Hao Y; Song K; Tan X; Ren L; Guo X; Zhou C; Li H; Wen J; Meng Y; Lin M; Zhang Y; Huang H; Wang L; Zheng W ACS Nano; 2022 Dec; 16(12):20739-20757. PubMed ID: 36454190 [TBL] [Abstract][Full Text] [Related]
16. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells. Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671 [TBL] [Abstract][Full Text] [Related]
17. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation. Ullah A; Wang K; Wu P; Oupicky D; Sun M Int J Nanomedicine; 2019; 14():2927-2944. PubMed ID: 31118614 [No Abstract] [Full Text] [Related]
18. Transcriptomic and proteomic investigation of the ameliorative effect of total polyphenolic glycoside extract on hepatic fibrosis in Lamiophlomis rotata Kudo via the AGE/RAGE pathway. Yang C; Geng X; Wan G; Song L; Wang Y; Zhou G; Wang J; Pan Z J Ethnopharmacol; 2024 Apr; 324():117720. PubMed ID: 38211823 [TBL] [Abstract][Full Text] [Related]
19. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341 [TBL] [Abstract][Full Text] [Related]
20. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. Lin Y; Yan M; Bai Z; Xie Y; Ren L; Wei J; Zhu D; Wang H; Liu Y; Luo J; Li X J Nanobiotechnology; 2022 Oct; 20(1):432. PubMed ID: 36183106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]